Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients

• Main Authors: Chenliang Zhou (Author), Chaofan Li (Author), Guo-Zhong Gong (Author), Shuang Wang (Author), Ji-Ming Zhang (Author), Dao-Zhen Xu (Author), Li-Min Guo (Author), Hong Ren (Author), Min Xu (Author), Qing Xie (Author), Chen Pan (Author), Jie Xu (Author), Zhongyu Hu (Author), Shuang Geng (Author), Xian Zhou (Author), Xianzheng Wang (Author), Xiaoyu Zhou (Author), Haili Mi (Author), Gan Zhao (Author), Wencong Yu (Author), Yu-Mei Wen (Author), Lihua Huang (Author), Xuan-Yi Wang (Author), Bin Wang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2017-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

An HBsAg-HBIG therapeutic vaccine (Yeast-derived Immune Complexes, YIC) for chronic hepatitis B (CHB) patients has undergone a series of clinical trials. The HBeAg sero-conversion rate of YIC varied from 21.9% to 14% depending on the immunization protocols from 6 to 12 injections. To analyze the imm...